• Home
  •  / Agios Pharmaceuticals
Agios Pharmaceuticals

Agios Pharmaceuticals


$203.2 M

FY, 2020

Market Capitalization

$1.7 B


Agios Pharmaceuticals Summary

Company summary

Agios Pharmaceuticals is a biopharmaceutical company passionately committed to applying its scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic disorders of metabolism, which are a subset of orphan genetic metabolic diseases.Agios is a first mover in using cellular metabolism, an unexploited area of biological research with disruptive potential, as a platform for developing potentially transformative medicines. The Company intends to apply its deep understanding of metabolism, coupled with its ability to create medicines that can inhibit or activate metabolic enzymes, to fundamentally change the way cancer and rare genetic disorders of metabolism are treated.Agios also develops drugs that focus on glycolysis, fatty acid metabolism, and autophagy. The Company's therapeutics are used in the areas of autoimmune, inflammatory, and neurological diseases.
Cambridge, MA, US | view all locations
Cybersecurity rating
ESG rating
out of 100 | View all ESG data

Key people

  • Scott Biller

    Scott Biller, Scientific Advisory Board member

  • Jim Burns

    Jim Burns, Chief Legal Officer

    • Sarah Gheuens

      Sarah Gheuens, Chief Medical Officer

    • Ellen Lopresti

      Ellen Lopresti, Chief People Officer

    LocationsView all

    1 location detected

    • Cambridge, MA HQ

      United States

      88 Sidney St

    Agios Pharmaceuticals Financials

    Summary financials

    Revenue (Q2, 2022)
    Cash (Q2, 2022)
    Enterprise value

    Footer menu